Sifalimumab is a human monoclonal antibody that binds to and neutralises the majority of IFN-_ subtypes. Sifalimumab is a promising treatment for adults with systemic lupus erythematosus (SLE).
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.